Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke

The investigators hypothesis focuses on the effect of riboflavin given for the first three hours of ischemic stroke, as a reducing agent of cerebral glutamate concentration. This administration would produce a reduction of excitotoxic damage and consequently generate clinical improvement, while a lower income and a better functional outcome of patients at three months.

Inclusion criteria

• Patients older than 18 years, both men and women.
• Patient or legal representative able to understand and sign the informed consent.
• Patients with suspected stroke within 3 hours of onset.

Exclusion criteria

• Women of childbearing age, with potential for pregnancy or breastfeeding.
• Patients with a score ≥ 2 point 1a in the NIHSS scale.
• Scale pre-stroke modified Rankin ≥ 2.
• Inability to prior testing image needed for the study.
• Previous disorders that may interfere with the interpretation of neurological scales.
• Treatment with probenecid, tricyclic antidepressants, phenothiazines, streptomycin, erythromycin, tyrothricin, tetracyclines and carbomycin, at the time of inclusion.